Jagsonpal Pharmaceuticals Ltd vs Jenburkt Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 209.5 as of 06 May 15:30 . The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 25.9 on March 2025 . This represents a CAGR of 16.25% over 5 yearsThe P/E Ratio of Jenburkt Pharmaceuticals Ltd changed from 11.1 on March 2021 to 13.9 on March 2025 . This represents a CAGR of 4.60% over 5 years The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 1433 crore on March 2025 . This represents a CAGR of 47.06% over 5 yearsThe Market Cap of Jenburkt Pharmaceuticals Ltd changed from ₹ 182.84 crore on March 2021 to ₹ 446.49 crore on March 2025 . This represents a CAGR of 19.55% over 5 years The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 67.37 crore as compare to the Dec '25 revenue of ₹ 75.92 crore. This represent the decline of -11.26% The revenue of Jenburkt Pharmaceuticals Ltd for the Mar '26 is ₹ 48.98 crore as compare to the Dec '25 revenue of ₹ 44.84 crore. This represent the growth of 9.23% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 14.33 crore as compare to the Dec '25 ebitda of ₹ 17.16 crore. This represent the decline of -16.49% The ebitda of Jenburkt Pharmaceuticals Ltd for the Mar '26 is ₹ 14.65 crore as compare to the Dec '25 ebitda of ₹ 9.24 crore. This represent the growth of 58.55% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 5.33 crore to ₹ 8.76 crore over 8 quarters. This represents a CAGR of 28.20% The net profit of Jenburkt Pharmaceuticals Ltd changed from ₹ 7.42 crore to ₹ 10.85 crore over 8 quarters. This represents a CAGR of 20.92% The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 yearsThe Dividend Payout of Jenburkt Pharmaceuticals Ltd changed from 28.37 % on March 2021 to 24.76 % on March 2025 . This represents a CAGR of -2.69% over 5 years .

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Limited, incorporated in 1985, was formed a joint venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family.
The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries.
It has more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe.
The organisation caters to government, semi-government institutions, missionary hospitals, public sector enterprises, etc. Apart from this. the Company operate manufacturing plant at Sihor-Gujarat, approved as per W.H.O (World Health Organisation) guidelines with current Good Manufacturing Practices (GMP) requirements.

FAQs for the comparison of Jagsonpal Pharmaceuticals Ltd and Jenburkt Pharmaceuticals Ltd

Which company has a larger market capitalization, Jagsonpal Pharmaceuticals Ltd or Jenburkt Pharmaceuticals Ltd?

Market cap of Jagsonpal Pharmaceuticals Ltd is 1,388 Cr while Market cap of Jenburkt Pharmaceuticals Ltd is 474 Cr

What are the key factors driving the stock performance of Jagsonpal Pharmaceuticals Ltd and Jenburkt Pharmaceuticals Ltd?

The stock performance of Jagsonpal Pharmaceuticals Ltd and Jenburkt Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jagsonpal Pharmaceuticals Ltd and Jenburkt Pharmaceuticals Ltd?

As of May 6, 2026, the Jagsonpal Pharmaceuticals Ltd stock price is INR ₹206.8. On the other hand, Jenburkt Pharmaceuticals Ltd stock price is INR ₹1074.5.

How do dividend payouts of Jagsonpal Pharmaceuticals Ltd and Jenburkt Pharmaceuticals Ltd compare?

To compare the dividend payouts of Jagsonpal Pharmaceuticals Ltd and Jenburkt Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.